Trials like DAPA-CKD and FIDELIO-DKD demonstrated the positive effects of dapagliflozin and finerenone regardless of MRA or SGLT2 inhibitor use at baseline, respectively. Here, SLC5A2 is linked to diabetic kidney disease.